Xenon (XENE) has released an update.
Xenon Pharmaceuticals has presented promising Phase 2 results for its depression drug azetukalner at the American Society of Clinical Psychopharmacology meeting, demonstrating early efficacy and potential safety advantages over existing antidepressants. The clinical trial showed a meaningful reduction in depression symptoms, with significant improvements noted in both the depression rating scale scores and anhedonia measures. Xenon is gearing up to advance azetukalner into Phase 3 trials later in the year, aiming to establish it as a novel treatment option for major depressive disorder.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.
